HCP
RPRX icon

Hexagon Capital Partners’s Royalty Pharma RPRX Stock Holding History

Hexagon Capital Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-715
Closed -$22.3K – 1373
2025
Q1 		$22.3K Buy
715
+1
+0.1% +$32 ﹤0.01% 720
2024
Q4 		$18.2K Buy
714
+365
+105% +$9.68K ﹤0.01% 818
2024
Q3 		$9.87K Buy
349
+13
+4% +$360 ﹤0.01% 929
2024
Q2 		$8.86K Sell
336
-108
-24% -$2.99K ﹤0.01% 903
2024
Q1 		$13.5K Sell
444
-105
-19% -$3.1K ﹤0.01% 776
2023
Q4 		$15.4K Sell
549
-69
-11% -$1.9K ﹤0.01% 722
2023
Q3 		$16.8K Buy
+618
New +$18.4K ﹤0.01% 610
2022
Q4 		– Sell
-9
Closed – – 1508
2022
Q3 		$0 Buy
+9
New +$384 ﹤0.01% 1416

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $3.44B AUM 20.03% 1-Year Est. Return